Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell P Fink

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Journal of Cardiothoracic and Vascular Anesthesia|October 7, 2008
A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypassElliott Bennett-Guerrero, Madhav Swaminathan, Alina M Grigore, et al.
Shock (Augusta, Ga.)|October 25, 2008
Beneficial effects of ethyl pyruvate in a mouse model of spinal cord injuryTiziana Genovese, Emanuela Esposito, Emanuela Mazzon, et al.
Radiation Research|November 2, 2007
Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiationMichael Epperly, Shunqian Jin, Suhua Nie, et al.
Critical Care Medicine|December 4, 2008
Ethyl pyruvate reduces the development of zymosan-induced generalized inflammation in miceRosanna Di Paola, Emanuela Mazzon, Tiziana Genovese, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2002
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammationLuis Ulloa, Mahendar Ochani, Huan Yang, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|February 21, 2017
Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trialLakhmir S Chawla, James A Russell, Sean M Bagshaw, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 17, 2004
Exogenous IL-6 inhibits acute inflammatory responses and prevents ischemia/reperfusion injury after intestinal transplantationKei Kimizuka, Atsunori Nakao, Michael A Nalesnik, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 31, 2005
The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide-induced high-mobility group box 1 secretion by RAW 264.7 cellsMeaghan E Killeen, Joshua A Englert, Donna Beer Stolz, et al.
Critical Care Medicine|September 22, 2007
Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted antioxidantsMitchell P Fink, Carlos A Macias, Jingbo Xiao, et al.
JAMA|December 11, 2002
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trialHoward L Corwin, Andrew Gettinger, Ronald G Pearl, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Journal of Cardiothoracic and Vascular Anesthesia|October 7, 2008
A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypassElliott Bennett-Guerrero, Madhav Swaminathan, Alina M Grigore, et al.
Shock (Augusta, Ga.)|October 25, 2008
Beneficial effects of ethyl pyruvate in a mouse model of spinal cord injuryTiziana Genovese, Emanuela Esposito, Emanuela Mazzon, et al.
Radiation Research|November 2, 2007
Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiationMichael Epperly, Shunqian Jin, Suhua Nie, et al.
Critical Care Medicine|December 4, 2008
Ethyl pyruvate reduces the development of zymosan-induced generalized inflammation in miceRosanna Di Paola, Emanuela Mazzon, Tiziana Genovese, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2002
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammationLuis Ulloa, Mahendar Ochani, Huan Yang, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|February 21, 2017
Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trialLakhmir S Chawla, James A Russell, Sean M Bagshaw, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 17, 2004
Exogenous IL-6 inhibits acute inflammatory responses and prevents ischemia/reperfusion injury after intestinal transplantationKei Kimizuka, Atsunori Nakao, Michael A Nalesnik, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 31, 2005
The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide-induced high-mobility group box 1 secretion by RAW 264.7 cellsMeaghan E Killeen, Joshua A Englert, Donna Beer Stolz, et al.
Critical Care Medicine|September 22, 2007
Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted antioxidantsMitchell P Fink, Carlos A Macias, Jingbo Xiao, et al.
JAMA|December 11, 2002
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trialHoward L Corwin, Andrew Gettinger, Ronald G Pearl, et al.
Pageof 15